Roche’s Vabysmo Advantage Over Eylea Hard To See In Latest Head-To-Head
Both Drugs Dosed Monthly
Executive Summary
Roche’s next-generation eye drug Vabysmo has enjoyed a strong launch, but new head-to-head trials in a potential new indication, retinal vein occlusion, appear to offers up few advantages over market leader Eylea.
You may also be interested in...
Regeneron Raises Possibility Of Quick CRL Resolution For High-Dose Eylea
On its Q2 earnings call, Regeneron said its 8mg formulation of aflibercept could obtain US FDA approval this quarter, despite receiving a complete response letter in June. Refiling’s fate tied to review of pozelimab.
Regeneron Raises Possibility Of Quick CRL Resolution For High-Dose Eylea
On its earnings call, Regeneron said its 8mg formulation of aflibercept could obtain US FDA approval this quarter, despite receiving a complete response letter in June. Refiling’s fate tied to review of pozelimab, which is manufactured in the same plant with fill/finish concerns.
‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies
Led by the duo who brought the first anti-VEGF drug to market, EyeBio aims to develop the next breakthrough eye therapy via a novel tri-specific antibody.